Statin Cost and Utilization Outcomes After Implementation of Reference-Based Pricing

In 2005, it was estimated that the United States spent $19.7 billion on 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor (statin) drug therapy. Strategies such as reference-based pricing (RBP), therapeutic interchange, and moving prescription drugs “behind the counter” (ie, requiring a pharmacist’s approval but not a physician’s prescription) have been developed to help control costs in various drug classes.

Read the entire article in American Journal of Pharmacy Benefits here.